CVRx 8-K: Operations, Officer Changes, Compensation Updates

TL;DR

**CVRx just dropped an 8-K hinting at financial updates and leadership changes.**

AI Summary

CVRx, Inc. filed an 8-K on January 8, 2024, reporting events that occurred on January 3, 2024. The filing indicates that the company is providing an update on its results of operations and financial condition, as well as information regarding the departure or election of directors or officers and their compensatory arrangements. This matters to investors because it signals potential changes in leadership or financial performance, which could impact the company's future direction and stock value.

Why It Matters

This filing signals potential shifts in CVRx's financial health and leadership, which are critical factors for investors assessing the company's stability and growth prospects.

Risk Assessment

Risk Level: medium — The filing mentions 'Results of Operations and Financial Condition' and 'Departure of Directors or Certain Officers,' which could indicate either positive or negative developments, creating uncertainty for investors.

Analyst Insight

A smart investor would await further details on the 'Results of Operations and Financial Condition' and the specifics of any 'Departure of Directors or Certain Officers' to understand the full implications before making investment decisions.

Key Players & Entities

• CVRx, Inc. (company) — the registrant filing the 8-K
• January 3, 2024 (date) — date of earliest event reported
• January 8, 2024 (date) — date the 8-K was filed
• 001-40545 (other) — Commission File Number for CVRx, Inc.

FAQ

Key Financial Figures

• $0.01 — ich registered Common stock, par value $0.01 per share CVRX The Nasdaq Global S
• $11.2 million — ted to be in the range of approximately $11.2 million to $11.3 million, representing an incre
• $11.3 m — range of approximately $11.2 million to $11.3 million, representing an increase of appr
• $7.2 million — 58% over fourth quarter 2022 revenue of $7.2 million. Total revenue generated in the fourth
• $10.2 million — pected to be comprised of approximately $10.2 million in U.S. heart failure revenue, $1.0 mil
• $1.0 million — million in U.S. heart failure revenue, $1.0 million in European revenue and $0.1 million in
• $0.1 million — e, $1.0 million in European revenue and $0.1 million in U.S. legacy revenue. Full Year 2023
• $39.2 million — ted to be in the range of approximately $39.2 million to $39.3 million, representing an incre
• $39.3 m — range of approximately $39.2 million to $39.3 million, representing an increase of appr
• $22.5 million — % to 75% over full year 2022 revenue of $22.5 million. Total revenue generated in 2023 is exp
• $34.6 million — pected to be comprised of approximately $34.6 million in U.S. heart failure revenue, $4.2 mil
• $4.2 million — million in U.S. heart failure revenue, $4.2 million in European revenue and $0.5 million in
• $0.5 million — e, $4.2 million in European revenue and $0.5 million in U.S. legacy revenue. As of December
• $91 million — 1, 2023, cash and cash equivalents were $91 million. The foregoing estimated financial res

Filing Documents

• tm242330d1_8k.htm (8-K) — 30KB
• tm242330d1_ex99-1.htm (EX-99.1) — 21KB
• 0001104659-24-002089.txt ( ) — 230KB
• cvrx-20240103.xsd (EX-101.SCH) — 3KB
• cvrx-20240103_lab.xml (EX-101.LAB) — 33KB
• cvrx-20240103_pre.xml (EX-101.PRE) — 22KB
• tm242330d1_8k_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, CVRx, Inc. (the "Company") issued a press release announcing certain preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023 . A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

02. Departure of Directors or Certain Officers; Election

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 8, 2024, the Company announced that its President and Chief Executive Officer, Nadim Yared, provided notice to the Company's Board of Directors (the "Board") of his plans to retire upon the completion of a deliberate succession process and the appointment of a successor. Both Mr. Yared and the Board are committed to a planful and deliberate process to identify his successor, and Mr. Yared will remain in his current role until a new Chief Executive Officer is appointed. The Board is currently conducting a search to identify a new Chief Executive Officer with the assistance of a leading executive search firm.

01. Other Events

Item 8.01. Other Events. As disclosed above, on January 8, 2024, the Company issued a press release announcing preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Total revenue for the fourth quarter of 2023 is expected to be in the range of approximately $11.2 million to $11.3 million, representing an increase of approximately 56% to 58% over fourth quarter 2022 revenue of $7.2 million. Total revenue generated in the fourth quarter of 2023 is expected to be comprised of approximately $10.2 million in U.S. heart failure revenue, $1.0 million in European revenue and $0.1 million in U.S. legacy revenue. Full Year 2023 Total revenue for full year 2023 is expected to be in the range of approximately $39.2 million to $39.3 million, representing an increase of approximately 74% to 75% over full year 2022 revenue of $22.5 million. Total revenue generated in 2023 is expected to be comprised of approximately $34.6 million in U.S. heart failure revenue, $4.2 million in European revenue and $0.5 million in U.S. legacy revenue. As of December 31, 2023, the Company had a total of 178 active implanting centers, as compared to 159 as of September 30, 2023. The number of sales territories in the U.S. increased by three to a total of 38 during the three months ended December 31, 2023. As of December 31, 2023, cash and cash equivalents were $91 million. The foregoing estimated financial results for the fourth quarter and full year 2023 are preliminary, unaudited and represent the most recent current information available to Company management. The Company's actual results may differ from these estimated financial results, including due to the completion of its financial closing procedures and final adjustments. The Company expects to issue full financial results for the fourth quarter and full year 2023 in late January 2024.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of CVRx, Inc., dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CVRx, Inc. Date: January 8, 2024 By: /s/ Jared Oasheim Name: Jared Oasheim Its: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR